JP2014148535A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014148535A5 JP2014148535A5 JP2014091125A JP2014091125A JP2014148535A5 JP 2014148535 A5 JP2014148535 A5 JP 2014148535A5 JP 2014091125 A JP2014091125 A JP 2014091125A JP 2014091125 A JP2014091125 A JP 2014091125A JP 2014148535 A5 JP2014148535 A5 JP 2014148535A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- dose
- cytarabine
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 8
- 229960000684 Cytarabine Drugs 0.000 claims 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- CGXLVFZJJOXEDF-UHFFFAOYSA-N 1,8-naphthyridine-3-carboxylic acid Chemical compound N1=CC=CC2=CC(C(=O)O)=CN=C21 CGXLVFZJJOXEDF-UHFFFAOYSA-N 0.000 claims 1
- -1 2-thiazolyl Chemical group 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 229960004562 Carboplatin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960000640 Dactinomycin Drugs 0.000 claims 1
- 108010092160 Dactinomycin Proteins 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 Etoposide Drugs 0.000 claims 1
- 229960002949 Fluorouracil Drugs 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 229960004857 Mitomycin Drugs 0.000 claims 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 1
- QDLHCMPXEPAAMD-QAIWCSMKSA-N Wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 claims 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 1
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims 1
Claims (10)
- 有効成分として(＋)−1,4−ジヒドロ−7−[(3Ｓ,4Ｓ)−3−メトキシ−4−(メチルアミノ)−1−ピロリジニル]−4−オキソ−1−(2−チアゾリル)−1,8−ナフチリジン−3−カルボン酸を含む、患者のガンの治療用医薬組成物であって、エトポシド、ダウノマイシン、5-FU、シタラビン、メトトレキサート、シスプラチン、カルボプラチン、マイトマイシンC、アクチノマイシンD、ゲルダナマイシン、及びウォートマンニンから選択される薬剤と組み合わせて共投与される、前記医薬組成物。
- 前記薬剤が、シタラビンである、請求項１記載の医薬組成物。
- (＋)−1,4−ジヒドロ−7−[(3Ｓ,4Ｓ)−3−メトキシ−4−(メチルアミノ)−1−ピロリジニル]−4−オキソ−1−(2−チアゾリル)−1,8−ナフチリジン−3−カルボン酸を約10 mg/m2 〜 100 mg/m2 の用量を投与するために適当な量の (＋)−1,4−ジヒドロ−7−[(3Ｓ,4Ｓ)−3−メトキシ−4−(メチルアミノ)−1−ピロリジニル]−4−オキソ−1−(2−チアゾリル)−1,8−ナフチリジン−3−カルボン酸を含む、請求項１記載の医薬組成物。
- 前記用量が約30 mg/m2 〜 75 mg/m2 である、請求項３記載の組成物。
- 前記用量が約40 mg/m2 〜 80 mg/m2 である、請求項３記載の組成物。
- 前記用量が約50 mg/m2 〜 90 mg/m2 である、請求項３記載の組成物。
- シタラビンが少なくとも100 mg/m2の用量で投与される、請求項１〜６のいずれか一項記載の組成物。
- 前記ガンが白血病である、請求項１〜７のいずれか一項記載の組成物。
- シタラビンが静脈内に投与される、請求項１〜８のいずれか一項記載の組成物。
- 患者のガンの治療方法であって、請求項１〜９のいずれか一項記載の組成物を該患者に投与することを含む、前記治療方法。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55357804P | 2004-03-15 | 2004-03-15 | |
| US60/553,578 | 2004-03-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012036919A Division JP2012140442A (ja) | 2004-03-15 | 2012-02-23 | Ｓｎｓ−５９５、及びその使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015140309A Division JP6352863B2 (ja) | 2004-03-15 | 2015-07-14 | Ｓｎｓ−５９５、及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014148535A JP2014148535A (ja) | 2014-08-21 |
| JP2014148535A5 true JP2014148535A5 (ja) | 2015-03-19 |
| JP5856644B2 JP5856644B2 (ja) | 2016-02-10 |
Family
ID=34993432
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007503987A Expired - Fee Related JP5317472B2 (ja) | 2004-03-15 | 2005-03-14 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2007503972A Expired - Fee Related JP5096913B2 (ja) | 2004-03-15 | 2005-03-14 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2011135675A Pending JP2011225590A (ja) | 2004-03-15 | 2011-06-17 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2012036919A Pending JP2012140442A (ja) | 2004-03-15 | 2012-02-23 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2014091125A Expired - Fee Related JP5856644B2 (ja) | 2004-03-15 | 2014-04-25 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2014180862A Expired - Fee Related JP6261477B2 (ja) | 2004-03-15 | 2014-09-05 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2015140309A Expired - Fee Related JP6352863B2 (ja) | 2004-03-15 | 2015-07-14 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2016248041A Pending JP2017095471A (ja) | 2004-03-15 | 2016-12-21 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2018038834A Pending JP2018119977A (ja) | 2004-03-15 | 2018-03-05 | Ｓｎｓ−５９５、及びその使用方法 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007503987A Expired - Fee Related JP5317472B2 (ja) | 2004-03-15 | 2005-03-14 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2007503972A Expired - Fee Related JP5096913B2 (ja) | 2004-03-15 | 2005-03-14 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2011135675A Pending JP2011225590A (ja) | 2004-03-15 | 2011-06-17 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2012036919A Pending JP2012140442A (ja) | 2004-03-15 | 2012-02-23 | Ｓｎｓ−５９５、及びその使用方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014180862A Expired - Fee Related JP6261477B2 (ja) | 2004-03-15 | 2014-09-05 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2015140309A Expired - Fee Related JP6352863B2 (ja) | 2004-03-15 | 2015-07-14 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2016248041A Pending JP2017095471A (ja) | 2004-03-15 | 2016-12-21 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2018038834A Pending JP2018119977A (ja) | 2004-03-15 | 2018-03-05 | Ｓｎｓ−５９５、及びその使用方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (12) | US7968565B2 (ja) |
| EP (4) | EP1729770B1 (ja) |
| JP (9) | JP5317472B2 (ja) |
| KR (1) | KR101169825B1 (ja) |
| CN (5) | CN103251589B (ja) |
| AT (2) | ATE493982T1 (ja) |
| AU (3) | AU2005222622B2 (ja) |
| BR (1) | BRPI0508700A (ja) |
| CA (3) | CA2559652C (ja) |
| CY (2) | CY1109741T1 (ja) |
| DE (2) | DE602005018333D1 (ja) |
| DK (3) | DK2295056T5 (ja) |
| ES (3) | ES2334802T3 (ja) |
| HK (1) | HK1097196A1 (ja) |
| HU (1) | HUE027266T2 (ja) |
| IL (2) | IL177946A (ja) |
| MX (2) | MXPA06010382A (ja) |
| NO (3) | NO338058B1 (ja) |
| NZ (2) | NZ549557A (ja) |
| PL (3) | PL2295056T3 (ja) |
| PT (2) | PT1725233E (ja) |
| SI (2) | SI1725233T1 (ja) |
| WO (2) | WO2005089756A1 (ja) |
| ZA (1) | ZA200607248B (ja) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2559652C (en) | 2004-03-15 | 2017-02-14 | Sunesis Pharmaceuticals, Inc. | Methods of using sns-595 in treating cancer |
| KR100989029B1 (ko) | 2004-09-17 | 2010-10-25 | 사일린 파마슈티칼스, 인크 | 세포 증식 억제제로서의 퀴놀론 동족체 |
| US7652134B2 (en) | 2004-09-17 | 2010-01-26 | Cylene Pharmaceuticals, Inc. | Methods for converting quinolone esters into quinolone amides |
| EP1926372A2 (en) * | 2005-08-19 | 2008-06-04 | Cylene Pharmaceuticals, Inc. | HUMAN RIBOSOMAL DNA(rDNA) AND RIBOSOMAL RNA (rRNA) NUCLEIC ACIDS AND USES THEREOF |
| US8580814B2 (en) * | 2006-04-03 | 2013-11-12 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
| CA2620915C (en) * | 2005-09-02 | 2014-03-25 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
| AU2006287149B2 (en) * | 2005-09-02 | 2013-05-23 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
| EP2043645A2 (en) | 2006-06-12 | 2009-04-08 | Sunesis Pharmaceuticals, Inc. | Compounds and compositions for treatment of cancer |
| US20100048609A1 (en) * | 2006-08-01 | 2010-02-25 | Jacobs Jeffrey W | Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid |
| DK2049109T3 (en) * | 2006-08-02 | 2016-01-11 | Sunesis Pharmaceuticals Inc | Combined use of (+) - 1,4-dihydro-7 - [(3S, 4S) -3-methoxy-4- (methylamino) -1-pyrrolidinyl] -4-oxo-1- (2-thiazolyl) -1,8-naphthyridine-3-carboxylic acid and cytarabine (Ara-C) for the treatment of leukemia |
| EP2209380A4 (en) * | 2007-10-09 | 2011-09-14 | Mark T Hamann | METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF |
| JP6029808B2 (ja) * | 2007-10-22 | 2016-11-24 | サネシス ファーマシューティカルズ， インコーポレイテッド | 併用療法における（＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸の使用方法 |
| AU2014277779B2 (en) * | 2007-10-22 | 2016-05-19 | Sunesis Pharmaceuticals, Inc. | METHODS OF USING (+)-1,4-DIHYDRO-7-[(3s,4s)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID IN COMBINATION THERAPY |
| EP2649997B1 (en) * | 2007-12-10 | 2019-01-23 | Sunesis Pharmaceuticals, Inc. | (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of myelodyspastic syndrome |
| ES2646093T3 (es) | 2008-12-31 | 2017-12-12 | Sunesis Pharmaceuticals, Inc. | Método de preparación del ácido (+)-1,4-dihidro-7-[(3S,4S)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftiridina-3-carboxílico |
| JP5936862B2 (ja) * | 2009-02-27 | 2016-06-22 | サネシス ファーマシューティカルズ， インコーポレイテッド | Ｂｒｃａ２活性が低下した癌対象の治療のためのｓｎｓ−５９５の使用方法 |
| UA110465C2 (en) * | 2009-09-04 | 2016-01-12 | Sunesis Pharmaceutecals Inc | Stable sns-595 composition |
| WO2011056566A2 (en) * | 2009-10-26 | 2011-05-12 | Sunesis Pharmaceuticals, Inc. | Compounds and methods for treatment of cancer |
| WO2013128232A1 (en) | 2012-02-27 | 2013-09-06 | Labs & Technological Holding Solea, S.L. | Monitoring and control of soil conditions |
| LT3459942T (lt) | 2012-04-24 | 2021-05-10 | Vertex Pharmaceuticals Incorporated | Dnr-pk inhibitoriai |
| AU2014244555B2 (en) | 2013-03-12 | 2018-06-28 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
| WO2014169067A1 (en) * | 2013-04-09 | 2014-10-16 | Merrimack Pharmaceuticals, Inc. | Compositions for improving outcomes of liposomal chemotherapy |
| WO2015000034A1 (en) * | 2013-07-02 | 2015-01-08 | Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) | Method for preventing and/or treating chronic traumatic encephalopathy-iii |
| JP6408569B2 (ja) | 2013-10-17 | 2018-10-17 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ｄｎａ−ｐｋ阻害剤としての（ｓ）−ｎ−メチル−８−（１−（（２’−メチル−［４，５’−ビピリミジン］−６−イル）アミノ）プロパン−２−イル）キノリン−４−カルボキサミドおよびその重水素化誘導体の共結晶 |
| KR101775356B1 (ko) * | 2015-07-06 | 2017-09-06 | 재단법인 아산사회복지재단 | Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법 |
| JP2019529475A (ja) | 2016-09-27 | 2019-10-17 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ｄｎａ損傷剤とｄｎａ−ｐｋ阻害剤との組合せ物を使用する、がんを処置するための方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US216316A (en) * | 1879-06-10 | Improvement in latches | ||
| US3021A (en) * | 1843-03-30 | Stove with elevated ovejst | ||
| US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| US5078996A (en) | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
| CZ292631B6 (cs) * | 1994-06-14 | 2003-11-12 | Dainippon Pharmaceutical Co., Ltd. | Deriváty pyridonkarboxylové kyseliny, protinádorové a farmakologické prostředky je obsahující |
| JP4323574B2 (ja) | 1995-12-13 | 2009-09-02 | 大日本住友製薬株式会社 | 抗腫瘍剤 |
| ATE237136T1 (de) * | 1997-01-13 | 2003-04-15 | Kudos Pharm Ltd | Assay, verbindungen, therapie und nachweisverfahren um zelluläre dns-reparatur- aktivität zu modulieren |
| US20020032216A1 (en) * | 1997-03-21 | 2002-03-14 | Lg Chemical Ltd. | Salt of naphthyridine carboxylic acid derivative |
| JP2001523977A (ja) | 1997-06-05 | 2001-11-27 | ザ ユニバーシティ オブ テキサス システム ボード オブ リージェンツ | Ａｐａｆ−１、ｃｅｄ−４ヒト相同体、カスパーゼ−３の活性化因子 |
| US6171857B1 (en) * | 1997-10-17 | 2001-01-09 | Brown University Research Foundatiion | Leucine zipper protein, KARP-1 and methods of regulating DNA dependent protein kinase activity |
| US5968921A (en) | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
| IL124015A0 (en) * | 1998-04-08 | 1999-01-26 | Yeda Res & Dev | Pharmaceutical compositions comprising a protein |
| JP4294121B2 (ja) | 1998-06-05 | 2009-07-08 | 大日本住友製薬株式会社 | ピリドンカルボン酸誘導体の製造方法およびその中間体 |
| WO2000000644A1 (en) * | 1998-06-30 | 2000-01-06 | Sloan-Kettering Institute For Cancer Research | Uses of dna-pk |
| JP2002540769A (ja) * | 1999-02-26 | 2002-12-03 | ザ ジョンズ ホプキンス ユニヴァーシティ | プログラム細胞死の新規抑制剤 |
| US6670144B1 (en) | 1999-02-26 | 2003-12-30 | Cyclacel, Ltd. | Compositions and methods for monitoring the phosphorylation of natural binding partners |
| US7163801B2 (en) * | 1999-09-01 | 2007-01-16 | The Burnham Institute | Methods for determining the prognosis for cancer patients using tucan |
| US6479541B1 (en) * | 2000-03-30 | 2002-11-12 | Baxter International | Amiodarone-containing parenteral administration |
| JP2004500849A (ja) * | 2000-05-20 | 2004-01-15 | キャンサー・リサーチ・テクノロジー・リミテッド | 薬剤スクリーニングシステム及びアッセイ |
| US7179912B2 (en) * | 2000-09-01 | 2007-02-20 | Icos Corporation | Materials and methods to potentiate cancer treatment |
| WO2002028387A1 (en) | 2000-10-03 | 2002-04-11 | Oncopharmaceutical, Inc. | Inhibitors of angiogenesis and tumor growth for local and systemic administration |
| EP1337275A4 (en) | 2000-11-02 | 2007-05-09 | Sloan Kettering Inst Cancer | METHOD FOR ENHANCING THE EFFICACY OF CYTOTOXIC AGENTS USING HSP 90 INHIBITORS |
| WO2003089573A2 (en) * | 2002-04-05 | 2003-10-30 | Fishel Richard A | Methods of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof |
| JP2006523681A (ja) * | 2003-03-24 | 2006-10-19 | ルイトポルド・ファーマシューティカルズ・インコーポレーテッド | Ｄｎａ−ｐｋ阻害剤としてのキサントン、チオキサントンおよびアクリジノン |
| CA2559652C (en) * | 2004-03-15 | 2017-02-14 | Sunesis Pharmaceuticals, Inc. | Methods of using sns-595 in treating cancer |
| AU2006287149B2 (en) | 2005-09-02 | 2013-05-23 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
| US8580814B2 (en) | 2006-04-03 | 2013-11-12 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
| EP2043645A2 (en) | 2006-06-12 | 2009-04-08 | Sunesis Pharmaceuticals, Inc. | Compounds and compositions for treatment of cancer |
| US20100048609A1 (en) | 2006-08-01 | 2010-02-25 | Jacobs Jeffrey W | Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid |
| DK2049109T3 (en) | 2006-08-02 | 2016-01-11 | Sunesis Pharmaceuticals Inc | Combined use of (+) - 1,4-dihydro-7 - [(3S, 4S) -3-methoxy-4- (methylamino) -1-pyrrolidinyl] -4-oxo-1- (2-thiazolyl) -1,8-naphthyridine-3-carboxylic acid and cytarabine (Ara-C) for the treatment of leukemia |
| JP6029808B2 (ja) | 2007-10-22 | 2016-11-24 | サネシス ファーマシューティカルズ， インコーポレイテッド | 併用療法における（＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸の使用方法 |
| EP2649997B1 (en) | 2007-12-10 | 2019-01-23 | Sunesis Pharmaceuticals, Inc. | (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of myelodyspastic syndrome |
| ES2646093T3 (es) | 2008-12-31 | 2017-12-12 | Sunesis Pharmaceuticals, Inc. | Método de preparación del ácido (+)-1,4-dihidro-7-[(3S,4S)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftiridina-3-carboxílico |
| JP5936862B2 (ja) | 2009-02-27 | 2016-06-22 | サネシス ファーマシューティカルズ， インコーポレイテッド | Ｂｒｃａ２活性が低下した癌対象の治療のためのｓｎｓ−５９５の使用方法 |
| CN101631081B (zh) | 2009-08-12 | 2011-06-08 | 华为技术有限公司 | 一种多级交换网 |
| UA110465C2 (en) | 2009-09-04 | 2016-01-12 | Sunesis Pharmaceutecals Inc | Stable sns-595 composition |
| WO2011056566A2 (en) | 2009-10-26 | 2011-05-12 | Sunesis Pharmaceuticals, Inc. | Compounds and methods for treatment of cancer |
-
2005
- 2005-03-14 CA CA2559652A patent/CA2559652C/en not_active Expired - Fee Related
- 2005-03-14 PT PT05731600T patent/PT1725233E/pt unknown
- 2005-03-14 JP JP2007503987A patent/JP5317472B2/ja not_active Expired - Fee Related
- 2005-03-14 CN CN201210307785.8A patent/CN103251589B/zh not_active Expired - Fee Related
- 2005-03-14 MX MXPA06010382A patent/MXPA06010382A/es active IP Right Grant
- 2005-03-14 DK DK10177951.0T patent/DK2295056T5/en active
- 2005-03-14 PL PL10177951T patent/PL2295056T3/pl unknown
- 2005-03-14 SI SI200531244T patent/SI1725233T1/sl unknown
- 2005-03-14 DK DK05732554.0T patent/DK1729770T3/da active
- 2005-03-14 BR BRPI0508700-7A patent/BRPI0508700A/pt not_active IP Right Cessation
- 2005-03-14 CA CA2559650A patent/CA2559650C/en not_active Expired - Fee Related
- 2005-03-14 HU HUE10177951A patent/HUE027266T2/en unknown
- 2005-03-14 US US11/080,102 patent/US7968565B2/en not_active Expired - Fee Related
- 2005-03-14 EP EP05732554A patent/EP1729770B1/en not_active Not-in-force
- 2005-03-14 DK DK05731600.2T patent/DK1725233T3/da active
- 2005-03-14 DE DE602005018333T patent/DE602005018333D1/de active Active
- 2005-03-14 CN CN201410477839.4A patent/CN104324029A/zh active Pending
- 2005-03-14 WO PCT/US2005/008036 patent/WO2005089756A1/en active Application Filing
- 2005-03-14 US US11/080,283 patent/US7989468B2/en not_active Expired - Fee Related
- 2005-03-14 AU AU2005222622A patent/AU2005222622B2/en not_active Ceased
- 2005-03-14 CN CN200910221540A patent/CN101703508A/zh active Pending
- 2005-03-14 CN CN201210307920.9A patent/CN103083316B/zh not_active Expired - Fee Related
- 2005-03-14 MX MX2011011851A patent/MX349188B/es unknown
- 2005-03-14 ES ES05732554T patent/ES2334802T3/es active Active
- 2005-03-14 ZA ZA200607248A patent/ZA200607248B/xx unknown
- 2005-03-14 NZ NZ549557A patent/NZ549557A/en not_active IP Right Cessation
- 2005-03-14 JP JP2007503972A patent/JP5096913B2/ja not_active Expired - Fee Related
- 2005-03-14 EP EP05731600A patent/EP1725233B1/en not_active Not-in-force
- 2005-03-14 CA CA2954578A patent/CA2954578A1/en not_active Abandoned
- 2005-03-14 PL PL05731600T patent/PL1725233T3/pl unknown
- 2005-03-14 EP EP10177951.0A patent/EP2295056B9/en not_active Not-in-force
- 2005-03-14 EP EP15202939.3A patent/EP3053579A1/en not_active Withdrawn
- 2005-03-14 ES ES10177951.0T patent/ES2566973T3/es active Active
- 2005-03-14 AT AT05731600T patent/ATE493982T1/de active
- 2005-03-14 ES ES05731600T patent/ES2358267T3/es active Active
- 2005-03-14 KR KR1020067021270A patent/KR101169825B1/ko active IP Right Grant
- 2005-03-14 DE DE602005025738T patent/DE602005025738D1/de active Active
- 2005-03-14 AU AU2005222607A patent/AU2005222607B2/en not_active Ceased
- 2005-03-14 PL PL05732554T patent/PL1729770T3/pl unknown
- 2005-03-14 SI SI200530890T patent/SI1729770T1/sl unknown
- 2005-03-14 WO PCT/US2005/008346 patent/WO2005089757A1/en active Application Filing
- 2005-03-14 CN CN200580015456.4A patent/CN1997368B/zh not_active Expired - Fee Related
- 2005-03-14 AT AT05732554T patent/ATE451924T1/de active
- 2005-03-14 PT PT05732554T patent/PT1729770E/pt unknown
- 2005-04-14 NZ NZ588060A patent/NZ588060A/en not_active IP Right Cessation
- 2005-09-02 US US11/218,653 patent/US20060063795A1/en active Pending
- 2005-09-02 US US11/218,387 patent/US20060025437A1/en active Pending
-
2006
- 2006-06-29 US US11/478,765 patent/US7829577B2/en not_active Expired - Fee Related
- 2006-09-07 IL IL177946A patent/IL177946A/en not_active IP Right Cessation
- 2006-10-12 NO NO20064647A patent/NO338058B1/no not_active IP Right Cessation
-
2007
- 2007-05-07 HK HK07104836.3A patent/HK1097196A1/xx not_active IP Right Cessation
-
2010
- 2010-01-21 CY CY20101100063T patent/CY1109741T1/el unknown
-
2011
- 2011-02-03 CY CY20111100114T patent/CY1111263T1/el unknown
- 2011-03-22 AU AU2011201277A patent/AU2011201277B2/en not_active Ceased
- 2011-04-27 US US13/095,111 patent/US20110263524A1/en not_active Abandoned
- 2011-06-13 US US13/159,258 patent/US8669270B2/en not_active Expired - Fee Related
- 2011-06-17 JP JP2011135675A patent/JP2011225590A/ja active Pending
-
2012
- 2012-02-23 JP JP2012036919A patent/JP2012140442A/ja active Pending
-
2013
- 2013-03-11 US US13/794,583 patent/US8822493B2/en not_active Expired - Fee Related
-
2014
- 2014-02-03 US US14/171,673 patent/US20140378505A1/en not_active Abandoned
- 2014-04-25 JP JP2014091125A patent/JP5856644B2/ja not_active Expired - Fee Related
- 2014-08-18 US US14/462,439 patent/US9980949B2/en not_active Expired - Fee Related
- 2014-09-05 JP JP2014180862A patent/JP6261477B2/ja not_active Expired - Fee Related
-
2015
- 2015-04-17 NO NO20150466A patent/NO339613B1/no not_active IP Right Cessation
- 2015-07-14 JP JP2015140309A patent/JP6352863B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-14 US US14/996,025 patent/US9757363B2/en not_active Expired - Fee Related
- 2016-09-26 IL IL248049A patent/IL248049A0/en unknown
- 2016-11-24 NO NO20161867A patent/NO20161867A1/no not_active Application Discontinuation
- 2016-12-21 JP JP2016248041A patent/JP2017095471A/ja active Pending
-
2018
- 2018-03-05 JP JP2018038834A patent/JP2018119977A/ja active Pending
- 2018-04-27 US US15/965,741 patent/US20180316309A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014148535A5 (ja) | ||
| JP2015227351A5 (ja) | ||
| JP2014040437A5 (ja) | ||
| EP3251674A3 (en) | Antiviral azasugar-containing nucleosides | |
| WO2015081133A3 (en) | Nucleotides for the treatment of liver cancer | |
| JP2017504611A5 (ja) | ||
| NZ709260A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| JP2011079858A5 (ja) | ||
| JP2013526525A5 (ja) | ||
| CL2014001437A1 (es) | Compuestos derivados de aril dihidropiridinona y piperidinona como inhibidores de monoacilglicerol aciltransferasa (mgat2); composicion y combinacion farmaceutica; y uso en el tratamiento y prevencion de diabetes, hiperglucemia, retinopatia, sindrome metabolico, entre otras enfermedades. | |
| JP2016539157A5 (ja) | ||
| JP2009539994A5 (ja) | ||
| MX2015012559A (es) | Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson. | |
| MY166288A (en) | Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt | |
| WO2011085643A8 (zh) | 吡啶并环衍生物 | |
| WO2016100949A3 (en) | Method and compositions for dissolving or solubilizing therapeutic agents | |
| WO2019244066A3 (en) | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | |
| WO2016040814A3 (en) | Disulfide polymers and methods of use | |
| AR079174A1 (es) | Composiciones para comprimidos desintegrables oralmente de ondansetron para prevenir nauseas y vomitos | |
| WO2015193517A3 (en) | Liquid pharmaceutical composition comprising pemetrexed | |
| JP2014148552A5 (ja) | ||
| JP2011500805A5 (ja) | ||
| MX2010004350A (es) | Metodos de uso del acido (+)-1,4-dihidro-7-[(3s,4s)]-3-metoxi-4-(m etilamino)-1-pirrolidinil-4-oxo-1-(2-tiazolil)-1, 8-naftiridina-3-carboxilico en terapias de combinacion. | |
| JP2014504636A5 (ja) | ||
| JP2007119497A5 (ja) |